NCT06083662View on ClinicalTrials.gov

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

November 30, 2023

Study Completion Date

December 30, 2024

Conditions
Metastatic CancerHER2 Gene Mutation
Interventions
DRUG

Neratinib Maleate

"* neratinib 240mg po daily~* herzuma 8mg/kg (loading) --\> 6mg/kg q3w"

Trial Locations (1)

Unknown

Korea university Guro hospital, Seoul

All Listed Sponsors
collaborator

Korean Cancer Study Group

OTHER

lead

Korea University Guro Hospital

OTHER